- Home
- TNXP vs CGTX Comparison
TNXP vs CGTX Comparison
Compare TNXP & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- CGTX
- Stock Information
- Founded
- TNXP 2007
- CGTX 2007
- Country
- TNXP United States
- CGTX United States
- Employees
- TNXP N/A
- CGTX N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- TNXP Health Care
- CGTX Health Care
- Exchange
- TNXP Nasdaq
- CGTX Nasdaq
- Market Cap
- TNXP 197.9M
- CGTX 158.8M
- IPO Year
- TNXP N/A
- CGTX 2021
- Fundamental
- Price
- TNXP $15.12
- CGTX $1.66
- Analyst Decision
- TNXP Buy
- CGTX Strong Buy
- Analyst Count
- TNXP 1
- CGTX 4
- Target Price
- TNXP $70.00
- CGTX $2.88
- AVG Volume (30 Days)
- TNXP 778.7K
- CGTX 1.0M
- Earning Date
- TNXP 11-10-2025
- CGTX 11-06-2025
- Dividend Yield
- TNXP N/A
- CGTX N/A
- EPS Growth
- TNXP N/A
- CGTX N/A
- EPS
- TNXP N/A
- CGTX N/A
- Revenue
- TNXP $10,299,000.00
- CGTX N/A
- Revenue This Year
- TNXP $14.79
- CGTX N/A
- Revenue Next Year
- TNXP $933.49
- CGTX N/A
- P/E Ratio
- TNXP N/A
- CGTX N/A
- Revenue Growth
- TNXP N/A
- CGTX N/A
- 52 Week Low
- TNXP $6.76
- CGTX $0.22
- 52 Week High
- TNXP $130.00
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- TNXP 35.51
- CGTX 53.76
- Support Level
- TNXP $13.70
- CGTX $1.30
- Resistance Level
- TNXP $18.25
- CGTX $1.55
- Average True Range (ATR)
- TNXP 1.28
- CGTX 0.14
- MACD
- TNXP 0.07
- CGTX -0.00
- Stochastic Oscillator
- TNXP 26.08
- CGTX 70.11
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.